INO-3107 and the PAPZIMEOS precedent · INO-3107 · Nov 2025 – Aug 2026
What did INOVIO say the PAPZIMEOS approval meant for INO-3107?
That the FDA would expect INO-3107 to show a clinically meaningful benefit over existing therapies, including PAPZIMEOS. In November 2025 INOVIO said this for filing acceptance; from March 2026, for approval.
EphemerisX Research · Published · 5 source documents · 1 min read
Short answer
INOVIO's risk factors say that, in light of PAPZIMEOS, it expects the FDA to require INO-3107 to show a clinically meaningful benefit over existing therapies, including PAPZIMEOS. The November 2025 10-Q applied that to the FDA accepting the filing; after the FDA accepted it in December, the 10-K applied it to approval.
What the evidence shows
November 10, 2025, before the application was accepted: we anticipate that the FDA will not accept the filing of our BLA for INO-3107 under the accelerated approval pathway unless we demonstrate at a minimum how INO-3107 provides a clinically meaningful benefit over existing therapies, including PAPZIMEOS
10-Q · Nov 10, 2025.
The FDA accepted the application on standard review in December 2025 and noted as a potential review issue its preliminary conclusion that the Company has not submitted adequate information to justify eligibility for the accelerated approval pathway
8-K · Dec 29, 2025.
March 12, 2026, the 10-K: we anticipate that the FDA will not approve our BLA for INO-3107 under the accelerated approval pathway unless we demonstrate that INO-3107 provides a clinically meaningful benefit over existing therapies, including PAPZIMEOS
10-K · Mar 12, 2026.
On the market: For RRP, Precigen received an unexpected traditional approval for PAPZIMEOS in August 2025 and launched the product commercially in the U.S. later in the year
10-K · Mar 12, 2026, and we may be at a potential competitive disadvantage in this indication, if approved, as INO-3107 would be a second entrant
10-K · Mar 12, 2026.
On the trial: from May 2026 the enrollment risk factor adds a reason, the recent availability of an approved immunotherapy
10-Q · May 13, 2026. INOVIO is not currently planning to seek approval for its BLA for INO-3107 under the traditional pathway, which could potentially require INOVIO to conduct a Phase 3 trial
10-Q · Aug 12, 2026. What the FDA flagged: What did the FDA flag when it accepted INO-3107's application?
Follow the thread
- How did PAPZIMEOS go from an accelerated-approval application to a traditional approval?“An unexpected traditional approval”
- What did the FDA flag when it accepted INO-3107's application?Accelerated-approval eligibility flagged
- Where does INO-3107's confirmatory trial stand in INOVIO's filings?“An approved immunotherapy” and enrollment
- What is on the public record before the FDA's October 30, 2026 goal date for INO-3107?A benefit over existing therapies
The documents, by date
The passages quoted
INOVIO Form 10-Q, filed November 10, 2025
For example, in light of the FDA’s approval of PAPZIMEOS (zopapogene imadenovec-drba) for the treatment of RRP in adults, we anticipate that the FDA will not accept the filing of our BLA for INO-3107 under the accelerated approval pathway unless we demonstrate at a minimum how INO-3107 provides a clinically meaningful benefit over existing therapies, including PAPZIMEOS.Open at the source →
INOVIO Form 8-K, filed December 29, 2025
The Company filed the BLA under the accelerated approval pathway. In the file acceptance letter, the FDA noted as a potential review issue its preliminary conclusion that the Company has not submitted adequate information to justify eligibility for the accelerated approval pathway. The Company plans to request a meeting with FDA to discuss next steps to remain eligible under the accelerated approval program. The Company is not currently planning to seek approval for INO-3107 under the traditional pathway.Open at the source →
INOVIO Form 10-K, filed March 12, 2026
For RRP, Precigen received an unexpected traditional approval for PAPZIMEOS in August 2025 and launched the product commercially in the U.S. later in the year. As a result, we may be at a potential competitive disadvantage in this indication, if approved, as INO-3107 would be a second entrant.Open at the source →
INOVIO Form 10-K, filed March 12, 2026
For example, in light of the FDA’s approval of PAPZIMEOS (zopapogene imadenovec-drba) for the treatment of RRP in adults, we anticipate that the FDA will not approve our BLA for INO-3107 under the accelerated approval pathway unless we demonstrate that INO-3107 provides a clinically meaningful benefit over existing therapies, including PAPZIMEOS.Open at the source →
INOVIO Form 10-Q, filed May 13, 2026
With respect to clinical trials of product candidates for rare diseases, such as our planned confirmatory trial of INO-3107 for the treatment of RRP, we may encounter difficulties in recruiting a sufficient number of patients to enroll in the trial due to the small number of patients with the disease and the recent availability of an approved immunotherapy.Open at the source →
INOVIO Form 10-Q, filed August 12, 2026
INOVIO is not currently planning to seek approval for its BLA for INO-3107 under the traditional pathway, which could potentially require INOVIO to conduct a Phase 3 trial, the design of which would need to be agreed with the FDA and would be at a substantial cost.Open at the source →